Clinical trial NCT02291497: Burden of Disease in Hypophosphatasia (HPP)
Official title: Non-interventional, Prospective, Single-center Investigation With Exploratory Data Analysis to Delineate the Variability and Frequency of Symptoms and Disease Manifestations in Adult HPP Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypophosphatasia
Lead sponsor: Wuerzburg University Hospital
Sponsor class: OTHER
First posted: 2014-11-14
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: see "Eligibility Criteria"

Brief summary: Hypophosphatasia (HPP) is a rare, inherited metabolic disease caused by inactivating mutations in the Alkaline Phosphatase (ALPL) gene, coding for the Tissue-nonspecific alkaline phosphatase (TNAP). Penetrance and disease severity is very heterogenous, ranging from stillbirth to adult-onset manifestations. Especially the latter are again characterized by an extremely broad spectrum of symptoms. This scope of variability makes it difficult to attribute individual patients' symptoms to the disease and distinguish them from HPP independent health issues. Especially in adult HPP patients, musculoskeletal problems, including (fragility-) fractures / bone bruise, joint pain, reduced mobility, muscular weakness and pain and reduced muscular endurance appear to reflect the prevailing burden of disease, especially with respect these patients dis-abilities of daily life.

To expand current knowledge of the natural history of the disease as well as on disease specific musculoskeletal deficits in HPP, all adult patients with established Diagnosis of HPP known at the Orthopedic Institute, University of Würzburg, will be offered to participate in a single, multimodal assessment of their disease history, current symptoms and disabilities, lab evaluations and clinical and technical analysis of their musculoskeletal status and capabilities.

Patients will be invited to a day long visit to the clinic in order to perform the following assessments:

A) Epidemiologic / anamnestic information B) Physical examination C) Structured questionnaires D) Laboratory examinations E) Clinical functional testing F) Technical Examinations


Eligibility criteria: Inclusion Criteria:

* Adult males and females (age ≥ 18 years)
* Established diagnosis of Hypophosphatasia
* Reduced Serum/Plasma ALP (Alkaline phosphatase)-Activity below age and sex specific reference range of the respective test kit applied (measured at least twice with a minimum 4 week interval)
* At least one of the items below:

  * Genetically secured ALPL-Mutation
  * Elevated PLP (Pyridoxal 5-Phosphate) (urine or serum), above ULN (Upper level of normal)
  * Symptoms of the disease
* Signed informed consent

Exclusion Criteria:

* Current / previous treatment with Asfotase alfa
* Current participation in another clinical study

Primary outcomes:
measure: Frequencies of main disease symptoms and main disease manifestations
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Wuerzburg
country: Germany
facility: Clinical Trial Unit, Orthopaedische Klinik Koenig-Ludwig-Haus, Lehrstuhl der Universitaet Wuerzburg
state: Bavaria
Study officials:
References:
citation: Weider M, Schlagenhauf U, Seefried L. Oral health status of adult hypophosphatasia patients: A cross-sectional study. J Clin Periodontol. 2022 Dec;49(12):1253-1261. doi: 10.1111/jcpe.13718. Epub 2022 Sep 7.